Close Menu

Lung Cancer

News and reporting on lung cancer.

Waters this week named the Center for Proteomics at the Translational Genomics Research Institute as one of its Centers of Innovation.

Proceeds from the financing will support the commercialization of Allegro's lead genomic test, BronchoGen, in 2012.

The test will be commercialized in the US by the company's recently formed sales team.

The study was done as part of a pilot study to sequence the tumors of patients with rare cancer types to help guide treatment.

The funds were raised in a Series A extension financing and will go toward the commercialization of its BronchoGen test in 2012.

Allegro CEO Mike Webb said the licensing agreement will support the "continued advancement" of the firm's BronchoGen test, including a planned commercial launch in the first half of 2012.

The IP licensed by Allegro relates to a gene expression-based platform that detects common molecular responses that occur throughout the respiratory tract in current and former smokers with lung cancer.

Using custom microarrays and bisulfite sequencing, researchers have garnered evidence of extensive shifts and variability in methylation patterns in the genomes of several types of cancers.

By testing 1,000 individuals with lung cancer for driver mutations in 10 genes, members of the Lung Cancer Mutation Consortium are finding mutations to help physicians offer more targeted treatment and clinical trial options for those with the disease.

A study published earlier this spring by OSU researchers identified a set of miRNA signatures in blood that could yield a new test for lung cancer development and prognosis.

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.